Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.

Ascierto PA, Bastholt L, Ferrucci PF, Hansson J, Márquez Rodas I, Payne M, Robert C, Thomas L, Utikal JS, Wolter P, Kudlac A, Tuson H, McKendrick J.

Melanoma Res. 2018 Aug;28(4):333-340. doi: 10.1097/CMR.0000000000000455.

PMID:
29750751
2.

Preventive Therapies for Chronic Migraine.

Balfagón G, Blanco-Rivero J, Márquez-Rodas I.

N Engl J Med. 2018 Feb 22;378(8):773-4. doi: 10.1056/NEJMc1716990. No abstract available.

3.

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.

Martín Algarra S, Soriano V, Fernández-Morales L, Berciano-Guerrero MÁ, Mujika K, Manzano JL, Puértolas Hernández T, Soria A, Rodríguez-Abreu D, Espinosa Arranz E, Medina Martínez J, Márquez-Rodas I, Rubió-Casadevall J, Ortega ME, Jurado García JM, Lecumberri Biurrun MJ, Palacio I, Rodríguez de la Borbolla Artacho M, Altozano JP, Castellón Rubio VE, García A, Luna P, Ballesteros A, Fernández O, López Martín JA, Berrocal A, Arance A.

Medicine (Baltimore). 2017 Dec;96(52):e9523. doi: 10.1097/MD.0000000000009523.

4.

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.

Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, Teixido C, Molina-Vila MA, Viteri S, De Los Llanos Gil M, Algarra SM, Perez-Ruiz E, Marquez-Rodas I, Rodriguez-Abreu D, Blanco R, Puertolas T, Royo MA, Rosell R.

Ther Adv Med Oncol. 2018 Jan 18;10:1758834017749748. doi: 10.1177/1758834017749748. eCollection 2018.

5.

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.

Echavarria I, López-Tarruella S, Picornell A, García-Saenz JÁ, Jerez Y, Hoadley K, Gómez HL, Moreno F, Monte-Millan MD, Márquez-Rodas I, Alvarez E, Ramos-Medina R, Gayarre J, Massarrah T, Ocaña I, Cebollero M, Fuentes H, Barnadas A, Ballesteros AI, Bohn U, Perou CM, Martin M.

Clin Cancer Res. 2018 Apr 15;24(8):1845-1852. doi: 10.1158/1078-0432.CCR-17-1912. Epub 2018 Jan 29.

PMID:
29378733
6.

CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma.

Samaniego R, Gutiérrez-González A, Gutiérrez-Seijo A, Sánchez-Gregorio S, García-Giménez J, Mercader E, Márquez-Rodas I, Avilés JA, Relloso M, Sánchez-Mateos P.

Cancer Immunol Res. 2018 Jan 23. doi: 10.1158/2326-6066.CIR-17-0198. [Epub ahead of print]

PMID:
29362221
7.

Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit.

Lobo M, López-Tarruella S, Luque S, Lizarraga S, Flores-Sánchez C, Bueno O, Solera J, Jerez Y, Del Val RG, Palomero MI, Cebollero M, Echavarría I, Torres G, Martín M, Márquez-Rodas I.

J Genet Couns. 2018 Aug;27(4):854-862. doi: 10.1007/s10897-017-0187-3. Epub 2017 Dec 15.

PMID:
29247312
8.

SEOM clinical guideline for the management of malignant melanoma (2017).

Berrocal A, Arance A, Castellon VE, de la Cruz L, Espinosa E, Cao MG, Larriba JLG, Márquez-Rodas I, Soria A, Algarra SM.

Clin Transl Oncol. 2018 Jan;20(1):69-74. doi: 10.1007/s12094-017-1768-1. Epub 2017 Nov 7.

9.

Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM).

Espinosa E, Márquez-Rodas I, Soria A, Berrocal A, Manzano JL, Gonzalez-Cao M, Martin-Algarra S; Spanish Melanoma Group (GEM).

Ann Transl Med. 2017 Oct;5(19):389. doi: 10.21037/atm.2017.08.10. Review.

10.

Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study.

Márquez-Rodas I, Pollán M, Escudero MJ, Ruiz A, Martín M, Santaballa A, Martínez Del Prado P, Batista N, Andrés R, Antón A, Llombart A, Fernandez Aramburu A, Adrover E, González S, Seguí MA, Calvo L, Lizón J, Rodríguez Lescure Á, Ramón Y Cajal T, Llort G, Jara C, Carrasco E, López-Tarruella S.

PLoS One. 2017 Oct 6;12(10):e0184181. doi: 10.1371/journal.pone.0184181. eCollection 2017.

11.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators.

N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.

12.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J.

N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.

13.

Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

López-Tarruella S, Jerez Y, Márquez-Rodas I, Echavarria I, Martin M.

Future Oncol. 2017 Oct;13(24):2137-2149. doi: 10.2217/fon-2017-0183. Epub 2017 Jul 31.

PMID:
28758424
14.

Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.

González-Rivera M, Lobo M, López-Tarruella S, Jerez Y, Del Monte-Millán M, Massarrah T, Ramos-Medina R, Ocaña I, Picornell A, Santillán Garzón S, Pérez-Carbornero L, García-Saenz JA, Gómez H, Moreno F, Márquez-Rodas I, Fuentes H, Martin M.

Breast Cancer Res Treat. 2017 Sep;165(2):471. doi: 10.1007/s10549-017-4396-0. No abstract available.

PMID:
28721639
15.

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.

Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain JF, Hodi FS, Wolchok JD.

JAMA Oncol. 2017 Nov 1;3(11):1511-1519. doi: 10.1001/jamaoncol.2017.1588.

PMID:
28662232
16.

Neratinib for the treatment of HER2-positive early stage breast cancer.

Echavarria I, López-Tarruella S, Márquez-Rodas I, Jerez Y, Martin M.

Expert Rev Anticancer Ther. 2017 Aug;17(8):669-679. doi: 10.1080/14737140.2017.1338954. Epub 2017 Jun 26. Review.

PMID:
28649882
17.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV.

Lancet Oncol. 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1. Epub 2017 Jun 4.

18.

Why do patients with thick melanoma have different outcomes? A retrospective epidemiological and survival analysis.

Rodríguez-Lomba E, Marquez-Rodas I, Mercader-Cidoncha E, Suárez-Fernández R, Avilés-Izquierdo JA.

Clin Transl Oncol. 2017 Aug;19(8):1055-1057. doi: 10.1007/s12094-017-1637-y. Epub 2017 Mar 1. No abstract available.

PMID:
28251497
19.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH Jr, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, Wolchok JD.

J Clin Oncol. 2017 Jan 10;35(2):226-235. Epub 2016 Nov 7.

20.

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

González-Cao M, Arance A, Piulats JM, Marquez-Rodas I, Manzano JL, Berrocal A, Crespo G, Rodriguez D, Perez-Ruiz E, Berciano M, Soria A, Castano AG, Espinosa E, Montagut C, Alonso L, Puertolas T, Aguado C, Royo MA, Blanco R, Rodríguez JF, Muñoz E, Mut P, Barron F, Martin-Algarra S; Spanish Melanoma Group.

Clin Transl Oncol. 2017 Jun;19(6):761-768. doi: 10.1007/s12094-016-1602-1. Epub 2017 Jan 4.

PMID:
28054320
21.

Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.

Echavarria I, Granja M, Bueno C, Lopez-Tarruella S, Peinado P, Sotelo M, Jerez Y, Moreno F, Torres G, Lobo M, Marquez-Rodas I, Del Monte-Millan M, Martín M, García-Saenz JA.

Breast Cancer Res Treat. 2017 Feb;162(1):181-189. doi: 10.1007/s10549-016-4098-z. Epub 2016 Dec 31.

PMID:
28040858
22.

Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital.

Márquez-Rodas I, Lobo M, Flores-Sanchez C, Sanz M, Luque S, Lizarraga S, González-Asanza C, Pajares JA, Peligros MI, Bueno O, Mata C, Lopez C, López-Tarruella S, Jerez Y, Muñoz-Martin A, Blanco M, Die-Trill M, Justel JP, Solera J, Martin M.

Oncology. 2017;92(2):68-74. doi: 10.1159/000452280. Epub 2016 Nov 18.

PMID:
27855387
23.

Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma.

Avilés-Izquierdo JA, Molina-López I, Rodríguez-Lomba E, Marquez-Rodas I, Suarez-Fernandez R, Lazaro-Ochaita P.

J Am Acad Dermatol. 2016 Nov;75(5):967-974. doi: 10.1016/j.jaad.2016.07.009. Epub 2016 Sep 16.

PMID:
27645105
24.

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.

Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness MK, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M.

Clin Cancer Res. 2017 Feb 1;23(3):649-657. doi: 10.1158/1078-0432.CCR-16-0162. Epub 2016 Jun 14.

25.

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.

González-Rivera M, Lobo M, López-Tarruella S, Jerez Y, Del Monte-Millán M, Massarrah T, Ramos-Medina R, Ocaña I, Picornell A, Santillán Garzón S, Pérez-Carbornero L, García-Saenz JA, Gómez H, Moreno F, Márquez-Rodas I, Fuentes H, Martin M.

Breast Cancer Res Treat. 2016 Apr;156(3):507-515. doi: 10.1007/s10549-016-3792-1. Epub 2016 Apr 15. Erratum in: Breast Cancer Res Treat. 2017 Sep;165(2):471.

PMID:
27083178
26.

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.

Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S.

Melanoma Res. 2016 Jun;26(3):278-83. doi: 10.1097/CMR.0000000000000254.

27.

Review: circulating tumor cells in the practice of breast cancer oncology.

Ramos-Medina R, Moreno F, Lopez-Tarruella S, Del Monte-Millán M, Márquez-Rodas I, Durán E, Jerez Y, Garcia-Saenz JA, Ocaña I, Andrés S, Massarrah T, González-Rivera M, Martin M.

Clin Transl Oncol. 2016 Aug;18(8):749-59. doi: 10.1007/s12094-015-1460-2. Epub 2015 Dec 8. Review.

PMID:
26646763
28.

Immune checkpoint inhibitors: therapeutic advances in melanoma.

Márquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, González-Cao M, Martín-Algarra S.

Ann Transl Med. 2015 Oct;3(18):267. doi: 10.3978/j.issn.2305-5839.2015.10.27. Review.

29.

The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.

Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Ramón Y Cajal T, Hernández-Agudo E, Heredia Soto V, Márquez-Rodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusidó M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ.

J Gynecol Oncol. 2016 Jan;27(1):e7. doi: 10.3802/jgo.2016.27.e7. Epub 2015 Nov 27.

30.

Exclusion criteria vs reality: dual BRAF/MEK inhibition and radiotherapy in a patient with melanoma metastatic to the brain and ECOG 3.

Márquez-Rodas I, Avilés-Izquierdo JA, Parra V, Álvarez-González A, Borrego P, Fernández-García P, Guzmán-de-Villoria JA, Jerez Y, Martin M.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000408.

PMID:
26350195
31.

Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial.

Casla S, López-Tarruella S, Jerez Y, Marquez-Rodas I, Galvão DA, Newton RU, Cubedo R, Calvo I, Sampedro J, Barakat R, Martín M.

Breast Cancer Res Treat. 2015 Sep;153(2):371-82. doi: 10.1007/s10549-015-3541-x. Epub 2015 Aug 21.

PMID:
26293147
32.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD.

N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.

33.

Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.

Márquez-Rodas I, Martín González M, Nagore E, Gómez-Fernández C, Avilés-Izquierdo JA, Maldonado-Seral C, Soriano V, Majem-Tarruella M, Palomar V, Maseda R, Martín-Carnicero A, Puertolas T, Godoy E, Cerezuela P, Ochoa de Olza M, Campos B, Perez-Ruiz E, Soria A, Gil-Arnaiz I, Gonzalez-Cao M, Galvez E, Arance A, Belon J, de la Cruz-Merino L, Martín-Algarra S; Spanish Multidisciplinary Group of Melanoma (GEM).

PLoS One. 2015 Apr 13;10(4):e0124239. doi: 10.1371/journal.pone.0124239. eCollection 2015.

34.

Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.

Kamieniak MM, Rico D, Milne RL, Muñoz-Repeto I, Ibáñez K, Grillo MA, Domingo S, Borrego S, Cazorla A, García-Bueno JM, Hernando S, García-Donas J, Hernández-Agudo E, Y Cajal TR, Robles-Díaz L, Márquez-Rodas I, Cusidó M, Sáez R, Lacambra-Calvet C, Osorio A, Urioste M, Cigudosa JC, Paz-Ares L, Palacios J, Benítez J, García MJ.

Mol Oncol. 2015 Feb;9(2):422-36. doi: 10.1016/j.molonc.2014.09.010. Epub 2014 Oct 5.

35.

Cost-Effectiveness of Ipilimumab for Previously Untreated Patients with Advanced Metastatic Melanoma in Spain.

Aceituno S, Canal C, Paz S, Gonzalez P, Marquez-Rodas I.

Value Health. 2014 Nov;17(7):A631. doi: 10.1016/j.jval.2014.08.2259. Epub 2014 Oct 26. No abstract available.

36.

Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore.

Pérez Ramírez S, Parra V, Avilés Izquierdo JA, Vicario JL, Martín M, Márquez-Rodas I.

Tumori. 2014 Jul-Aug;100(4):144e-7e. doi: 10.1700/1636.17932.

PMID:
25296606
37.

MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors.

Tanic M, Yanowski K, Gómez-López G, Rodriguez-Pinilla MS, Marquez-Rodas I, Osorio A, Pisano DG, Martinez-Delgado B, Benítez J.

Int J Cancer. 2015 Feb 1;136(3):593-602. doi: 10.1002/ijc.29021. Epub 2014 Jun 19.

38.

Running away from side effects: physical exercise as a complementary intervention for breast cancer patients.

Casla S, Hojman P, Márquez-Rodas I, López-Tarruella S, Jerez Y, Barakat R, Martín M.

Clin Transl Oncol. 2015 Mar;17(3):180-96. doi: 10.1007/s12094-014-1184-8. Epub 2014 Jun 4. Review.

PMID:
24894838
39.

MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.

Tanic M, Andrés E, Rodriguez-Pinilla SM, Marquez-Rodas I, Cebollero-Presmanes M, Fernandez V, Osorio A, Benítez J, Martinez-Delgado B.

Br J Cancer. 2013 Nov 12;109(10):2724-34. doi: 10.1038/bjc.2013.612. Epub 2013 Oct 8.

40.

Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer.

Martín M, Custodio S, de Las Casas ML, García-Sáenz JÁ, de la Torre JC, Bellón-Cano JM, López-Tarruella S, Vidaurreta-Lazaro M, de la Orden V, Jerez Y, Márquez-Rodas I, Casado A, Sastre J, Díaz-Rubio E.

Oncologist. 2013;18(8):917-23. doi: 10.1634/theoncologist.2012-0479. Epub 2013 Jul 19.

41.

Evaluation of a heredofamilial cancer unit in increasing family history collection and genetic counseling referrals among Spanish oncologists at a university hospital.

Márquez-Rodas I, López-Tarruella S, Jerez Y, Cavanagh M, Custodio S, López-Trabada D, Moya B, Pérez S, Rupérez AB, Martín M.

J Genet Couns. 2014 Feb;23(1):108-13. doi: 10.1007/s10897-013-9617-z. Epub 2013 Jun 16.

PMID:
23771728
42.

Epidemiological changes in cutaneous melanoma: retrospective study of 969 cases (1996-2010).

Avilés-Izquierdo JA, Lázaro-Ochaita P, Suárez-Fernández R, Márquez-Rodas I, Parra-Blanco V, Escat-Cortés JL.

Rev Clin Esp (Barc). 2013 Mar;213(2):81-7. doi: 10.1016/j.rce.2012.06.006. Epub 2012 Aug 5. English, Spanish.

PMID:
22874464
43.

Neratinib (HKI-272) in the treatment of breast cancer.

López-Tarruella S, Jerez Y, Márquez-Rodas I, Martín M.

Future Oncol. 2012 Jun;8(6):671-81. doi: 10.2217/fon.12.66. Review.

PMID:
22764764
44.

Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene.

Tanic M, Yanowsky K, Rodriguez-Antona C, Andrés R, Márquez-Rodas I, Osorio A, Benitez J, Martinez-Delgado B.

PLoS One. 2012;7(6):e38847. doi: 10.1371/journal.pone.0038847. Epub 2012 Jun 11.

45.

Family history record and hereditary cancer risk perception according to National Cancer Institute criteria in a Spanish medical oncology service: a retrospective study.

Márquez-Rodas I, López-Trabada D, Rupérez Blanco AB, Custodio Cabello S, Peligros Gómez MI, Orera Clemente M, Calvo FA, Martín M.

Oncology. 2012;82(1):30-4. doi: 10.1159/000335960. Epub 2012 Jan 26.

PMID:
22286392
46.

A new era in the treatment of melanoma: from biology to clinical practice.

Márquez-Rodas I, Martín Algarra S, Avilés Izquierdo JA, Custodio Cabello S, Martín M.

Clin Transl Oncol. 2011 Nov;13(11):787-92. doi: 1007/s12094-011-0734-6. Review.

PMID:
22082642
47.

Cirrhosis decreases vasoconstrictor response to electrical field stimulation in rat mesenteric artery: role of calcitonin gene-related peptide.

Blanco-Rivero J, Márquez-Rodas I, Sastre E, Cogolludo A, Pérez-Vizcaíno F, del Campo L, Nava MP, Balfagón G.

Exp Physiol. 2011 Mar;96(3):275-86. doi: 10.1113/expphysiol.2010.055822. Epub 2010 Dec 10.

48.

[Melanoma of male urethra: A clinical case].

Cabezón Gutiérrez L, Márquez-Rodas I, Soria Lovelle A, Martín Marino A, Alvarez Alvarez R, Muñoz Martín AJ.

Actas Urol Esp. 2010 Jul;34(7):651-2. Spanish. No abstract available.

PMID:
20540890
49.

[Perivascular innervation of the superior mesenteric artery: pathophysiological implications].

Sastre E, Márquez-Rodas I, Blanco-Rivero J, Balfagón G.

Rev Neurol. 2010 Jun 16;50(12):727-37. Review. Spanish.

50.

[Positron emission tomography for the study of solitary pulmonary nodules].

Márquez Rodas I, de Miguel Díez J, Alvarez-Sala JL.

Arch Bronconeumol. 2008 Sep;44(9):493-8. Review. Spanish.

Supplemental Content

Loading ...
Support Center